Literature DB >> 11911758

Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US Army women.

Andrew R Wiesen1, Christopher T Littell.   

Abstract

CONTEXT: Substantial concern surrounds the potential health effects of the anthrax vaccine, particularly the potential adverse effects on reproductive processes.
OBJECTIVE: To determine whether receipt of anthrax vaccination by reproductive-aged women has an effect on pregnancy rates. DESIGN, SETTING, AND PATIENTS: Cohort study, based on information from a computer database, of women aged 17 to 44 years who were stationed at Fort Stewart, Ga, or Hunter Army Airfield, Ga, from January 1999 through March 2000. MAIN OUTCOME MEASURES: Pregnancy and birth rates and adverse birth outcomes.
RESULTS: Of a total of 4092 women, 3136 received at least 1 dose of the anthrax vaccine. There was a total of 513 pregnancies, with 385 following at least 1 dose of anthrax vaccine. The pregnancy rate ratio (before and after adjustment for marital status, race, and age) comparing vaccinated with unvaccinated women was 0.94 (95% confidence interval [CI], 0.8-1.2; P =.60). There were 353 live births and 25 pregnancies lost to follow-up. The birth odds ratio after anthrax vaccination (before and after adjustment for marital status and age) was 0.9 (95% CI, 0.5-1.4; P =.55). After adjusting for age, the odds ratio for adverse birth outcome after receiving at least 1 dose of anthrax vaccination was 0.9 (95% CI, 0.4-2.4; P =.88). However, this study did not have sufficient power to detect adverse birth outcomes.
CONCLUSION: Anthrax vaccination had no effect on pregnancy and birth rates or adverse birth outcomes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11911758     DOI: 10.1001/jama.287.12.1556

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  5 in total

1.  Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial.

Authors:  Tracy Pondo; Charles E Rose; Stacey W Martin; Wendy A Keitel; Harry L Keyserling; Janiine Babcock; Scott Parker; Robert M Jacobson; Gregory A Poland; Michael M McNeil
Journal:  Vaccine       Date:  2014-04-24       Impact factor: 3.641

2.  Major Birth Defects after Vaccination Reported to the Vaccine Adverse Event Reporting System (VAERS), 1990 to 2014.

Authors:  Pedro L Moro; Janet Cragan; Paige Lewis; Lakshmi Sukumaran
Journal:  Birth Defects Res       Date:  2017-07-17       Impact factor: 2.344

Review 3.  Emerging infectious disease outbreaks: old lessons and new challenges for obstetrician-gynecologists.

Authors:  Denise J Jamieson; Jane E Ellis; Daniel B Jernigan; Tracee A Treadwell
Journal:  Am J Obstet Gynecol       Date:  2006-04-21       Impact factor: 8.661

Review 4.  Recent developments in the understanding and use of anthrax vaccine adsorbed: achieving more with less.

Authors:  Jarad M Schiffer; Michael M McNeil; Conrad P Quinn
Journal:  Expert Rev Vaccines       Date:  2016-03-25       Impact factor: 5.683

5.  Conference report on public health and clinical guidelines for anthrax.

Authors:  Eric Jacob Stern; Kristin Broome Uhde; Sean Vincent Shadomy; Nancy Messonnier
Journal:  Emerg Infect Dis       Date:  2008-04       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.